Corcept Therapeutics (CORT)

Generated: July 25, 2026

Red Dot

Statistics

Metric	Value
Last Close	$114.49
Blended Price Target	80.24
Blended Margin of Safety	-29.9% Overvalued
Rule of 40 (Next)	60.1%
Rule of 40 (Current)	50.2%
FCF-ROIC	15.2%
Sales Growth Next Year	44.9%
Sales Growth Current Year	35.0%
Sales 3-Year Avg	24.7%
Industry	Biotechnology

Analysis

Corcept Therapeutics has the profile of a high-quality specialty pharmaceutical business with real commercial traction, but not a fully insulated one. Its revenue outlook appears durable because the company still has room to expand penetration in Cushing’s syndrome while also building a second product base in oncology, yet the durability is tied to successful execution in a narrow set of indications rather than to broad platform breadth. ^[1]^[5]

Revenue is partly recurring and partly transaction-driven: the core product franchise can produce repeat prescribing, but the company does not enjoy subscription-like predictability, and sales still depend on treatment starts, refill persistence, distribution execution, and regulatory status. That makes Corcept more predictable than a typical one-shot biotech, but less stable than a diversified pharma company. ^[1]^[5]

The moat is anchored in specialized clinical know-how, physician familiarity, and regulatory and intellectual-property assets, not in network effects or switching costs. That is a meaningful moat in orphan and specialty medicine, but it is still vulnerable to generic pressure, label changes, and competitors that can reach the same prescribers with lower-friction access. Management has shown an ability to convert scientific assets into commercial revenue and to keep investing ahead of growth, which is a positive sign, but the business remains concentrated enough that leadership quality must be judged by sustained execution rather than strategy alone. ^[1]^[5]

What the Company Does

Corcept develops and sells medicines that modulate cortisol, and it currently makes most of its money from Korlym, its approved therapy for endogenous Cushing’s syndrome. The company is also advancing relacorilant and other pipeline assets aimed at expanding into Cushing’s and oncology, with commercial plans that extend beyond its legacy franchise. ^[1]^[5]

The revenue mix is still dominated by the Cushing’s business, while the newer oncology opportunity is in its early commercial or pre-commercial phase. Recent company materials emphasize growth initiatives around both Cushing’s syndrome and the launch of Lifyorli for platinum-resistant ovarian cancer, but a recent segment breakdown was not available in the disclosed materials reviewed here. ^[1]^[5]

Revenue Recurrence & Predictability

Corcept’s revenue is transactional with repeat-use characteristics, not subscription-based or contract-based. Patients can remain on therapy for extended periods, so sales can recur over time, but the company still depends on physician prescribing, patient access, refill adherence, and specialty-pharmacy fulfillment rather than on automatic contractual revenue. ^[1]^[5]

That means the business has moderate predictability, not high predictability. The core franchise is more stable than a single-dose or one-time-treatment business because chronic therapy can generate ongoing sales, but revenue remains exposed to changes in diagnosis rates, patient attrition, payer friction, and competitive entry. ^[1]^[5]

Revenue Growth Durability

Corcept can plausibly sustain above-market growth for several more years if it continues to expand penetration in underdiagnosed Cushing’s syndrome and executes a successful oncology launch. The growth runway is supported by a small starting base relative to the commercial opportunity and by management’s willingness to invest ahead of demand. ^[1]^[5]

The main tailwind is that Corcept is still early in the process of fully monetizing its cortisol biology franchise. The main headwinds are more structural: the addressable market is specialized, the business is concentrated, and any setback in regulation, market access, or competitive exclusivity can materially change the growth trajectory. ^[5]

Economic Moat

Corcept’s moat comes from intangible assets more than from structural scale advantages. Its prescription franchise is built on clinical evidence, physician familiarity, and a focused commercial infrastructure that is tuned to a narrow specialist audience, which is meaningful in an orphan-disease setting. ^[1]^[5]

The moat is real but not widening cleanly. It could strengthen if oncology broadens the commercial base and if relacorilant reaches additional approved uses, but it could also narrow if patent protection weakens or if competitors gain a cleaner path to the same prescribers and payers. Corcept does not have network effects, and switching costs are limited once alternatives exist. ^[5]

Management & Leadership

Corcept appears to be founder-led, with long-tenured leadership guiding both the science and the commercialization strategy. That matters because the company’s business model depends on disciplined development choices and careful sequencing of launches rather than broad-market scale. ^[5]

The leadership record is strongest in building and defending a specialized franchise while continuing to fund pipeline expansion. The company has also shown a willingness to return capital, including substantial share repurchases in 2025, which signals confidence but also reflects the need to balance cash deployment against a still-evolving growth portfolio. ^[3]^[5]

Key Risks

The biggest business risk is regulatory and patent disruption. Corcept’s core economics depend on protecting its specialty franchise long enough to monetize it, and any loss of exclusivity, labeling setback, or approval delay can quickly affect the revenue base. ^[5]^[8]

A second risk is execution risk in pipeline conversion. Corcept is trying to become more than a one-product company, but oncology and broader cortisol-related programs require successful clinical data, regulatory clearance, and commercial adoption, all of which can fail independently. ^[5]

A third risk is commercial concentration and access friction. Because the company sells into a narrow specialty market, it depends heavily on a limited prescriber base, payer acceptance, and specialty-distribution execution, which makes revenue more sensitive to operational issues than the headline growth rate suggests. ^[1]^[5]

Sources

Featured in GreenDot Stocks Analysis

GreenDot Stocks Screen Update — Week of July 25, 2026 July 25, 2026
GreenDot Stocks Screen Update — Week of July 17, 2026 July 17, 2026
GreenDot Stocks Screen Update — Week of July 11, 2026 July 11, 2026
GreenDot Stocks Screen Update — Week of July 4, 2026 July 4, 2026
GreenDot Stocks Screen Update — Week of June 27, 2026 June 27, 2026